Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5
Li, Q., et al
Click [...] To view or add a comment, sign in $NVO has started a Phase 1 trial for its new obesity drug candidate LX9851, developed with Lexicon Pharmaceuticals The drug is oral and works differently from current GLP-1 treatments, targeting fat metabolism and satiety signals The study will assess safety in overweight and obese patients, with results expected in Q1 2027 Lexicon receives a $10M milestone payment and could earn up to $1B plus royalties if successful #stocks #Investing To view or add a comment, sign in 16,926 followers
However, it is always advisable to consult a healthcare professional before combining multiple products to ensure safety and optimal results
BMJ Open 14(3):e082257 Maggini S, Maldonado P, Cardim P, Fernandez Newball C, Sota Latino E (2017) Vitamins C, D and zinc: synergistic roles in immune function and infections
Remember that GLP-1 drugs slow down digestion
US$ 21.07
US$ 21.37
US$ 21.28
US$ 20.99
US$ 23.90
US$ 24.13
![Physiologic effects of GLP-1 (adapted from Granata et al. [11])](https://www.researchgate.net/publication/359199250/figure/fig1/AS:11431281081130351@1661532031197/Physiologic-effects-of-GLP-1-adapted-from-Granata-et-al-11.png)
